{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T05:19:49Z","timestamp":1712207989016},"reference-count":39,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"New Jersey Governor's Council for Medical Research and Treatment of Autism"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.neuropharm.2012.06.014","type":"journal-article","created":{"date-parts":[[2012,6,18]],"date-time":"2012-06-18T22:23:15Z","timestamp":1340058195000},"page":"837-841","source":"Crossref","is-referenced-by-count":3,"title":["Reduced effect of stimulation of AMPA receptors on cerebral O2 consumption in a rat model of autism"],"prefix":"10.1016","volume":"63","author":[{"given":"Harvey R.","family":"Weiss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parneet","family":"Grewal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oak Z.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2012.06.014_bib1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1023\/A:1022238706604","article-title":"Plasma amino acid levels in children with autism and their families","volume":"33","author":"Aldred","year":"2003","journal-title":"J.\u00a0Autism Dev. Disord."},{"key":"10.1016\/j.neuropharm.2012.06.014_bib2","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1113\/jphysiol.2007.144154","article-title":"Glutamate receptor-dependent increments in lactate, glucose and oxygen metabolism evoked in rat cerebellum in\u00a0vivo","volume":"586","author":"Caesar","year":"2008","journal-title":"J.\u00a0Physiol."},{"key":"10.1016\/j.neuropharm.2012.06.014_bib3","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.pbb.2011.02.003","article-title":"Glutamate receptor dysfunction and drug targets across models of autism spectrum disorders","volume":"100","author":"Carlson","year":"2012","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2012.06.014_bib4","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1161\/01.RES.69.2.414","article-title":"Effects of MK-801 on cerebral regional oxygen consumption in focal cerebral ischemia in rats","volume":"69","author":"Chi","year":"1991","journal-title":"Circ. Res."},{"key":"10.1016\/j.neuropharm.2012.06.014_bib5","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/01616412.1999.11740935","article-title":"A\u00a0nonNMDA antagonist, GYKI 52466 improves microscopic O2 balance in the cortex during focal cerebral ischemia","volume":"21","author":"Chi","year":"1999","journal-title":"Neurol. Res."},{"key":"10.1016\/j.neuropharm.2012.06.014_bib6","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s00221-002-1310-7","article-title":"Effects of inhibition of neuronal nitric oxide synthase on NMDA-induced changes in cerebral blood flow and oxygen consumption","volume":"148","author":"Chi","year":"2003","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.neuropharm.2012.06.014_bib7","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1007\/s11064-007-9559-7","article-title":"Calpain inhibition protects spinal motoneurons from the excitotoxic effects of AMPA in\u00a0vivo","volume":"33","author":"Corona","year":"2008","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2012.06.014_bib8","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.expneurol.2006.03.021","article-title":"Different patterns of axonal damage after intracerebral injection of malonate or AMPA","volume":"200","author":"Cuthill","year":"2006","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2012.06.014_bib9","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1365-2788.2009.01208.x","article-title":"From mTOR to cognition: molecular and cellular mechanisms of cognitive impairments in tuberous sclerosis","volume":"53","author":"Ehninger","year":"2009","journal-title":"J.\u00a0Intellect. Disabil. Res.: JIDR"},{"key":"10.1016\/j.neuropharm.2012.06.014_bib10","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.molmed.2010.10.002","article-title":"Rapamycin for treating tuberous sclerosis and autism spectrum disorders","volume":"17","author":"Ehninger","year":"2011","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.neuropharm.2012.06.014_bib11","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0306-4522(98)00015-3","article-title":"Brain regional substrates for the actions of the novel wake-promoting agent modafinil in the rat: comparison with amphetamine","volume":"87","author":"Engber","year":"1998","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2012.06.014_bib12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.spen.2006.01.009","article-title":"The neurobiology of tuberous sclerosis complex","volume":"13","author":"Ess","year":"2006","journal-title":"Semin. Pediatr. Neurol."},{"key":"10.1016\/j.neuropharm.2012.06.014_bib13","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1097\/01.WCB.0000138665.25305.7C","article-title":"The AMPA receptor potentiator LY404187 increases cerebral glucose utilization and c-fos expression in the rat","volume":"24","author":"Fowler","year":"2004","journal-title":"J.\u00a0Cereb. Blood Flow Metab."},{"key":"10.1016\/j.neuropharm.2012.06.014_bib14","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1359-6446(04)03039-9","article-title":"Autism: a target of pharmacotherapies?","volume":"9","author":"Gerlai","year":"2004","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.neuropharm.2012.06.014_bib15","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s11065-008-9076-8","article-title":"The \u2018fractionable autism triad\u2019: a review of evidence from behavioural, genetic, cognitive and neural research","volume":"18","author":"Happe","year":"2008","journal-title":"Neuropsychol. Rev."},{"key":"10.1016\/j.neuropharm.2012.06.014_bib16","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1176\/ajp.2006.163.7.1252","article-title":"Volumetric analysis and three-dimensional glucose metabolic mapping of the striatum and thalamus in patients with autism spectrum disorders","volume":"163","author":"Haznedar","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.06.014_bib17","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1528-1167.2007.01035.x","article-title":"Tuberous sclerosis complex and epilepsy: recent developments and future challenges","volume":"48","author":"Holmes","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2012.06.014_bib18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/00129785-200505040-00004","article-title":"The autism genome project: goals and strategies","volume":"5","author":"Hu-Lince","year":"2005","journal-title":"Am. J. Pharmacogenomics: Genomics-related Research in Drug Development and Clinical Practice"},{"key":"10.1016\/j.neuropharm.2012.06.014_bib19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0387-7604(02)00006-2","article-title":"The relationship between 99mTc-HMPAO brain SPECT and the scores of real life rating scale in autistic children","volume":"24","author":"Kaya","year":"2002","journal-title":"Brain Dev."},{"key":"10.1016\/j.neuropharm.2012.06.014_bib20","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1203\/01.PDR.0000147727.78571.07","article-title":"Effects of rapamycin in the Eker rat model of tuberous sclerosis complex","volume":"57","author":"Kenerson","year":"2005","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.neuropharm.2012.06.014_bib21","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1136\/jmg.2003.012757","article-title":"Genotype and psychological phenotype in tuberous sclerosis","volume":"41","author":"Lewis","year":"2004","journal-title":"J.\u00a0Med. Genet."},{"key":"10.1016\/j.neuropharm.2012.06.014_bib22","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.brainres.2006.05.064","article-title":"Partially enhanced thalamocortical functional connectivity in autism","volume":"1104","author":"Mizuno","year":"2006","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2012.06.014_bib23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s10803-005-0040-7","article-title":"Enhanced perceptual functioning in autism: an update, and eight principles of autistic perception","volume":"36","author":"Mottron","year":"2006","journal-title":"J.\u00a0Autism Dev. Disord."},{"key":"10.1016\/j.neuropharm.2012.06.014_bib24","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1212\/WNL.57.9.1618","article-title":"Postmortem brain abnormalities of the glutamate neurotransmitter system in autism","volume":"57","author":"Purcell","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2012.06.014_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopsych.2011.01.015","article-title":"Auditory magnetic mismatch field latency: a biomarker for language impairment in autism","author":"Roberts","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.06.014_bib26","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1001\/archpsyc.1985.01790280026003","article-title":"Brain metabolism in autism. Resting cerebral glucose utilization rates as measured with positron emission tomography","volume":"42","author":"Rumsey","year":"1985","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.06.014_bib27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.biopsych.2005.06.007","article-title":"Neural correlates of executive function in autistic spectrum disorders","volume":"59","author":"Schmitz","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.06.014_bib28","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1152\/physiol.00033.2009","article-title":"Regulation of ionotropic glutamate receptors by their auxiliary subunits","volume":"25","author":"Tomita","year":"2010","journal-title":"Physiology (Bethesda)"},{"key":"10.1016\/j.neuropharm.2012.06.014_bib29","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1179\/016164103101202129","article-title":"17 Beta-estradiol suppresses AMPA-induced increases in regional cerebral O2 consumption","volume":"25","author":"Vaks","year":"2003","journal-title":"Neurol. Res."},{"key":"10.1016\/j.neuropharm.2012.06.014_bib30","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(03)14471-6","article-title":"Autism","volume":"362","author":"Volkmar","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2012.06.014_bib31","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1471-4159.2005.03538.x","article-title":"Enhanced episodic-like memory and kindling epilepsy in a rat model of tuberous sclerosis","volume":"96","author":"Waltereit","year":"2006","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2012.06.014_bib32","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s11065-008-9074-x","article-title":"Autism overflows: increasing prevalence and proliferating theories","volume":"18","author":"Waterhouse","year":"2008","journal-title":"Neuropsychol. Rev."},{"key":"10.1016\/j.neuropharm.2012.06.014_bib33","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0006-8993(02)03158-X","article-title":"17Beta-estradiol blocks NMDA-induced increases in regional cerebral O(2) consumption","volume":"951","author":"Weiss","year":"2002","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2012.06.014_bib34","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ijdevneu.2008.01.002","article-title":"Cerebral O(2) consumption in young Eker rats, effects of GABA blockade: implications for autism","volume":"26","author":"Weiss","year":"2008","journal-title":"Int. J. Dev. Neurosci."},{"key":"10.1016\/j.neuropharm.2012.06.014_bib35","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.brainres.2009.08.022","article-title":"Effects of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor blockade on increased cerebral O(2) consumption in Eker rats","volume":"1294","author":"Weiss","year":"2009","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2012.06.014_bib36","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1002\/jnr.21378","article-title":"Increased cerebral oxygen consumption in Eker rats and effects of N-methyl-D-aspartate blockade: implications for autism","volume":"85","author":"Weiss","year":"2007","journal-title":"J.\u00a0Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2012.06.014_bib37","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/08830738040190090701","article-title":"Autism and tuberous sclerosis","volume":"19","author":"Wiznitzer","year":"2004","journal-title":"J.\u00a0Child. Neurol."},{"key":"10.1016\/j.neuropharm.2012.06.014_bib38","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.nbd.2007.07.015","article-title":"Abnormal glutamate homeostasis and impaired synaptic plasticity and learning in a mouse model of tuberous sclerosis complex","volume":"28","author":"Zeng","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2012.06.014_bib39","first-page":"H626","article-title":"Oxy- and carboxyhemoglobin saturation determination in frozen small vessels","volume":"260","author":"Zhu","year":"1991","journal-title":"Am. J. Physiol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390812002729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390812002729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,30]],"date-time":"2019-06-30T03:12:28Z","timestamp":1561864348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390812002729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0028390812002729"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2012.06.014","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}